There are currently 2781 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Advance Care Planning in the Emergency Department
NCT05209880
Recruiting
This is a two-armed, parallel-design, pre-/post-intervention assessment study. The investigators will conduct a randomized controlled trial for ED GOAL on a cohort of 120 older adults with serious illness to collect patient-centered outcomes and determine preliminary efficacy on increasing advance care planning engagement (self-reported and/or in the electronic medical record) one month after leaving the emergency department. The investigators will also conduct qualitative interviews with partic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Congestive Heart Failure, Metastatic Cancer, Chronic Kidney Disease Requiring Chronic Dialysis, Chronic Obstructive Pulmonary Disease
Register for Updates
SIRT With Tremelimumab and Durvalumab for Resectable HCC
NCT05701488
Recruiting
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: Durvalumab (a type of immunotherapy) Tremelimumab (a type of immunotherapy) Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
Register for Updates
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
NCT05138458
Recruiting
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2023
Locations: Dana-Farber/Mass General Brigham Cancer Care, Boston, Massachusetts
Conditions: Cell Therapy, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy
Register for Updates
SCI-Lynx: A Mobile Platform for Physical Activity Social Support for People With SCI Pilot Study
NCT05764135
Recruiting
Physical activity is important to maintain health, fitness, and function in people with spinal cord injury (SCI) and social support is one of the most effective ways to increase physical activity participation. However, a large proportion of people with SCI are physically inactive and do not engage in recreational activities due to environmental and physical challenges. Many people with SCI also experience challenges with social connection, which may make engaging in physical activities more dif... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Spinal Cord Injuries
Register for Updates
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
NCT03059485
Recruiting
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/16/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Acute Myelogenous Leukemia
Register for Updates
Electronic Strategies for Tailored Exercise to Prevent FallS
NCT04993781
Recruiting
The objectives of this proposal are to evaluate the eSTEPS CDS (eSTEPS) in a cluster randomized controlled trial. The intervention includes the following: 1) A machine learning-based fall injury risk screening algorithm to improve traditional fall risk screening. 2) Provider BPA and/or Care Gap and Smart Set to provide CDS that helps primary care providers develop a tailored fall prevention exercise plan in the context of a Medicare Wellness Visit and 3) eSTEPS Patient App and exercise tools to... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
06/16/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Falls, Fall Injury, Exercise Self-Efficacy, Falls Self-Efficacy
Register for Updates
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
NCT05161429
Recruiting
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
Gender:
All
Ages:
30 years and above
Trial Updated:
06/16/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
NCT05767359
Recruiting
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: Cilta-cel (or chimeric antigen receptor T cells) Cyclophosphamide (a lymphodepleting chemotherapy) Fludarabine (a lymphodepleting chemotherapy)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/16/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma, Smoldering Multiple Myeloma
Register for Updates
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385
Recruiting
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a Dose Expansion: To investigate the safety and tolerability of DS-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/15/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer
Register for Updates
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
NCT04773782
Recruiting
This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/14/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor
Register for Updates
Imaging Brain Fluids During Breathing
NCT05180981
Recruiting
This study will perform magnetic resonance imaging (MRI) measurements of hemodynamics and cerebrospinal fluid flow across breathing tasks and during breath-locked neuromodulation.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/14/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Healthy
Register for Updates
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
NCT04339140
Recruiting
This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. The name of the study drug involved in this study is: Zafirlukast
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Ovarian Cancer
Register for Updates